Literature DB >> 29364495

New evidence on oral L. plantarum P17630 product in women with history of recurrent vulvovaginal candidiasis (RVVC): a randomized double-blind placebo-controlled study.

R Vladareanu1, D Mihu, M Mitran, C Mehedintu, A Boiangiu, M Manolache, S Vladareanu.   

Abstract

OBJECTIVE: To evaluate activity and tolerability of an oral product containing the specific probiotic strain Lactobacillus plantarum P17630 on vaginal colonization of lactic acid bacteria. PATIENTS AND METHODS: L. plantarum P17630 (5x109 CFU/capsule) or placebo were formulated in capsules and administrated orally to a total of 93 women with a history of recurrent vulvovaginal candidiasis over a period of 3 treatment cycles (15 days/cycle) separated by 15-day wash-out intervals. Vulvovaginal examinations and vaginal mycological culture, including Nugent score and Lactobacillary grade (LBG), were assessed at baseline, at day 45 and at day 90 (end of the study).
RESULTS: Probiotic intake significantly improved lactobacilli colonization on vaginal epithelial cells. The results demonstrated a significant difference in LBG score when comparing day 0 to day 45 (p=0.000016) and to day 90 (p=0.001415) in women treated with L. plantarum P17630. No evidence of improvement in LBG score was recorded in women who received placebo (p<0.005). The increased lactobacilli adhesion was associated with the improvement of clinical signs such as redness, swelling, and discharge.
CONCLUSIONS: This study demonstrates that the administration of oral probiotic Lactobacillus plantarum P17630 improves vagina colonization of acid lactic bacteria (an increase of vaginal LBG score) and suggests the use of this oral product to successfully prevent episodes of vulvovaginal candidiasis. The clinical study described in this article is registered in the ISRCTN registry with trial registration ID ISRCTN12669692.

Entities:  

Mesh:

Year:  2018        PMID: 29364495     DOI: 10.26355/eurrev_201801_14128

Source DB:  PubMed          Journal:  Eur Rev Med Pharmacol Sci        ISSN: 1128-3602            Impact factor:   3.507


  5 in total

Review 1.  Treatment for recurrent vulvovaginal candidiasis (thrush).

Authors:  Georga Cooke; Cathy Watson; Laura Deckx; Marie Pirotta; Jane Smith; Mieke L van Driel
Journal:  Cochrane Database Syst Rev       Date:  2022-01-10

Review 2.  The impact of the Fungus-Host-Microbiota interplay upon Candida albicans infections: current knowledge and new perspectives.

Authors:  Christophe d'Enfert; Ann-Kristin Kaune; Leovigildo-Rey Alaban; Sayoni Chakraborty; Nathaniel Cole; Margot Delavy; Daria Kosmala; Benoît Marsaux; Ricardo Fróis-Martins; Moran Morelli; Diletta Rosati; Marisa Valentine; Zixuan Xie; Yoan Emritloll; Peter A Warn; Frédéric Bequet; Marie-Elisabeth Bougnoux; Stephanie Bornes; Mark S Gresnigt; Bernhard Hube; Ilse D Jacobsen; Mélanie Legrand; Salomé Leibundgut-Landmann; Chaysavanh Manichanh; Carol A Munro; Mihai G Netea; Karla Queiroz; Karine Roget; Vincent Thomas; Claudia Thoral; Pieter Van den Abbeele; Alan W Walker; Alistair J P Brown
Journal:  FEMS Microbiol Rev       Date:  2021-05-05       Impact factor: 16.408

Review 3.  Probiotics, Their Extracellular Vesicles and Infectious Diseases.

Authors:  A Paula Domínguez Rubio; Cecilia L D'Antoni; Mariana Piuri; Oscar E Pérez
Journal:  Front Microbiol       Date:  2022-03-30       Impact factor: 5.640

4.  Comparing the Effect of Probiotic and Fluconazole on Treatment and Recurrence of Vulvovaginal Candidiasis: a Triple-Blinded Randomized Controlled Trial.

Authors:  Zahra Mollazadeh-Narestan; Parisa Yavarikia; Aziz Homayouni-Rad; Hossein Samadi Kafil; Sakineh Mohammad-Alizadeh-Charandabi; Pourya Gholizadeh; Mojgan Mirghafourvand
Journal:  Probiotics Antimicrob Proteins       Date:  2022-10-05       Impact factor: 5.265

Review 5.  Probiotic lactobacilli in formulas and hygiene products for the health of the urogenital tract.

Authors:  María Elena Fátima Nader-Macías; Priscilla Romina De Gregorio; Jessica Alejandra Silva
Journal:  Pharmacol Res Perspect       Date:  2021-10
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.